Testing for growth hormone deficiency in adults: doing without growth hormone-releasing hormone.

What It Covers

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in this review publication.

This article summarizes recent advances in testing for growth hormone deficiency (GHD) in adults, focusing on critical appraisal of existing growth hormone (GH) provocative tests as well as newer tests in development.

Why It Was Studied

Due to the current unavailability of the arginine-GHRH test in the USA, when ITT is contraindicated or impractical the researchers recommend the glucagon stimulation testing as the GH provocative test of choice.

Who the Included Studies Covered

PubMed indexes the participants as adults, both men and women.

What Was Measured

Due to the current unavailability of the arginine-GHRH test in the USA, when ITT is contraindicated or impractical the researchers recommend the glucagon stimulation testing as the GH provocative test of choice.

PubMed files the paper under topics including Arginine, Growth Hormone-Releasing Hormone, Guidelines as Topic, Hypoglycemia, Hypopituitarism, Insulin and Insulin-Like Growth Factor I.

What This Means in Plain Language

This is a review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Current opinion in endocrinology, diabetes, and obesity), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.